Skip to main content

Table 1 Demographics and laboratory data of screened patients in the WRHI001 South African Cohort

From: Is laboratory screening prior to antiretroviral treatment useful in Johannesburg, South Africa? Baseline findings of a clinical trial

Variable

Proportion or central measure

Population demographics and health status

Female n (%)

432 (57%)

Mean age (sd)

33.9 (7.7)

Nationality n (%)

 South African

431 (57%)

 Zimbabwean

287 (38%)

 Other African countries

40 (5%)

Marital status n (%)

 Married

174 (24%)

 Divorced or separate

12 (2%)

 Single

554 (75%)

Employed n (%)

551 (75%)

Current alcohol use n (%)

269 (36%)

Current smoking n (%)

116 (16%)

WHO clinical stage

 I

433 (59%)

 II

164 (22%)

 III

119 (16%)

 IV

20 (3%)

Median CD4 cells/μL at screening (IQR), n = 755a

208 (118-299)

Median plasma viral load copies/mL (IQR)

64,782 (17,646–186,662)

Laboratory screening tests prior to antiretroviral treatment

Creatinine clearance n < 50 mL/min (%)

4 (1%)

Microalbumin-to-creatinine ratio mg/mmol n (%)

 3.4–33.9

40 (5%)

  > 34.0

2 (0%)

Urine dipstick n (%)

 Proteinuria 1+

60 (8%)

 Proteinuria 2+

14 (2%)

 Proteinuria 3+

7 (1%)

Hepatitis B surface antigen positive n (%)

60 (8%)

Abnormal ALT/AST IU/L n (%) in all patients

 40–99 (1-2.4 X normal)

145 (19%)

 100–199 (2.5-4.9 X normal)

22 (3%)

  ≥ 200 (≥5 X normal)

4 (1%)

Abnormal ALT/AST IU/L n (%) If hepatitis B positive

 40–99

19 (32%)

 100–199

2 (3%)

  ≥ 200

2 (3%)

Anaemia in females n (%)

 8–10.0 g/dL

40 (9%)

  < 8.0 g/dL

10 (2%)

Anaemia in males n (%)

 

 8–10.0 g/dL

13 (4%)

  < 8.0 g/dL

2 (1%)

Neutrophil count

  < 0.75 × 10^9 /L n (%)

7 (1%)

 Median cells (IQR)

2.2 (1.6-2.9)

Platelet counts (cells/μl) n (%)

  < 50,000

3 (0)

 50,000--125,000

25 (3)

  1. a16 patients were excluded from the trial for reasons other than CD4 count, and thus CD4 tests were not done. IQR - inter-quartile range. sd - standard deviation